Switch theme
Sign up to access all valuation multiples
Embla Medical hf is is an Iceland-based company that operates within the field of medical equipment and supplies sector. The Company is active in the development and distribution of products in the fields of non-invasive prosthetics, medical braces and supports. Embla Medical operates within three business segments of the non-invasive orthopedics market; Prosthetics and Neuro Orthotics; Bracing and Supports; and Patient Care. Key revenue is generated from Prosthetics and Neuro Orthotics; segment.
1971
4.2K+
LTM Revenue $6.1B
LTM EBITDA $1.2B
$2.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Embla Medical has a last 12-month revenue (LTM) of $6.1B and a last 12-month EBITDA of $1.2B.
In the most recent fiscal year, Embla Medical achieved revenue of $129M and an EBITDA of $25.6M.
Embla Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Embla Medical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.1B | XXX | $129M | XXX | XXX | XXX |
| Gross Profit | $3.3B | XXX | $80.5M | XXX | XXX | XXX |
| Gross Margin | 55% | XXX | 63% | XXX | XXX | XXX |
| EBITDA | $1.2B | XXX | $25.6M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| EBIT | $818M | XXX | $17.0M | XXX | XXX | XXX |
| EBIT Margin | 13% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $504M | XXX | $10.3M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $40.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Embla Medical's stock price is DKK 33 (or $5).
Embla Medical has current market cap of DKK 13.9B (or $2.1B), and EV of DKK 16.8B (or $2.5B).
See Embla Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.5B | $2.1B | XXX | XXX | XXX | XXX | $0.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Embla Medical has market cap of $2.1B and EV of $2.5B.
Embla Medical's trades at 19.7x EV/Revenue multiple, and 99.0x EV/EBITDA.
Equity research analysts estimate Embla Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Embla Medical has a P/E ratio of 27.6x.
See valuation multiples for Embla Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.1B | XXX | $2.1B | XXX | XXX | XXX |
| EV (current) | $2.5B | XXX | $2.5B | XXX | XXX | XXX |
| EV/Revenue | 2.8x | XXX | 19.7x | XXX | XXX | XXX |
| EV/EBITDA | 14.0x | XXX | 99.0x | XXX | XXX | XXX |
| EV/EBIT | 20.5x | XXX | 149.0x | XXX | XXX | XXX |
| EV/Gross Profit | 5.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 27.6x | XXX | 204.1x | XXX | XXX | XXX |
| EV/FCF | 40.8x | XXX | 218.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEmbla Medical's last 12 month revenue growth is 2%
Embla Medical's revenue per employee in the last FY averaged $31K, while opex per employee averaged $15K for the same period.
Embla Medical's rule of 40 is 21% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Embla Medical's rule of X is 26% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Embla Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 2% | XXX | 176% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | -1% | XXX | 187% | XXX | XXX | XXX |
| Rule of 40 | 21% | XXX | 22% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 26% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $31K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $15K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 36% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 49% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Embla Medical acquired XXX companies to date.
Last acquisition by Embla Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Embla Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Embla Medical founded? | Embla Medical was founded in 1971. |
| Where is Embla Medical headquartered? | Embla Medical is headquartered in Denmark. |
| How many employees does Embla Medical have? | As of today, Embla Medical has 4.2K+ employees. |
| Who is the CEO of Embla Medical? | Embla Medical's CEO is Mr. Sveinn Solvason. |
| Is Embla Medical publicy listed? | Yes, Embla Medical is a public company listed on CSE. |
| What is the stock symbol of Embla Medical? | Embla Medical trades under EMBLA ticker. |
| When did Embla Medical go public? | Embla Medical went public in 2009. |
| Who are competitors of Embla Medical? | Similar companies to Embla Medical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Embla Medical? | Embla Medical's current market cap is $2.1B |
| What is the current revenue of Embla Medical? | Embla Medical's last 12 months revenue is $6.1B. |
| What is the current revenue growth of Embla Medical? | Embla Medical revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of Embla Medical? | Current revenue multiple of Embla Medical is 2.8x. |
| Is Embla Medical profitable? | Yes, Embla Medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Embla Medical? | Embla Medical's last 12 months EBITDA is $1.2B. |
| What is Embla Medical's EBITDA margin? | Embla Medical's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Embla Medical? | Current EBITDA multiple of Embla Medical is 14.0x. |
| What is the current FCF of Embla Medical? | Embla Medical's last 12 months FCF is $412M. |
| What is Embla Medical's FCF margin? | Embla Medical's last 12 months FCF margin is 7%. |
| What is the current EV/FCF multiple of Embla Medical? | Current FCF multiple of Embla Medical is 40.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
